Explore the words cloud of the PRECIOUS project. It provides you a very rough idea of what is the project "PRECIOUS" about.
The following table provides information about the project.
STICHTING KATHOLIEKE UNIVERSITEIT
|Coordinator Country||Netherlands [NL]|
|Total cost||8˙291˙217 €|
|EC max contribution||8˙291˙217 € (100%)|
1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
|Duration (year-month-day)||from 2016-05-01 to 2021-04-30|
Take a look of project's partnership.
|1||STICHTING KATHOLIEKE UNIVERSITEIT||NL (NIJMEGEN)||coordinator||1˙802˙005.00|
|2||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||984˙650.00|
|3||ITEOS THERAPEUTICS||BE (GOSSELIES)||participant||952˙222.00|
|4||EVONIK NUTRITION & CARE GMBH||DE (ESSEN)||participant||838˙549.00|
|5||UNIVERSITAT KONSTANZ||DE (KONSTANZ)||participant||828˙126.00|
|6||SPECIALIZED MEDICAL SERVICES-ONCOLOGY BV||NL (SCHIPHOL)||participant||722˙689.00|
|7||FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI||IT (Milan)||participant||693˙206.00|
|8||ONCOARENDI THERAPEUTICS SPOLKA AKCYJNA||PL (WARSZAWA)||participant||617˙854.00|
|9||USTAV MAKROMOLEKULARNI CHEMIE AV CRVVI||CZ (PRAHA 6)||participant||464˙238.00|
|10||IOX THERAPEUTICS LIMITED||UK (LONDON)||participant||242˙295.00|
|11||TTOPSTART BV||NL (UTRECHT)||participant||145˙377.00|
PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy. With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer. Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity.
PRECIOUS will tackle 2 bottlenecks: 1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression 2. Large scale GMP production of nanomedicines, and initiate a multimodal immunotherapy Phase I trial.
We want to solve these bottlenecks by: Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour. Objective 2: Clinical Phase I trial to show efficacy. Nanomedicines will be used by 1) injection of vaccines to evoke immune responses and 2) injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression.
To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies. Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.
|year||authors and title||journal||last update|
Giuseppe Lo Russo, Massimo Moro, Michele Sommariva, Valeria Cancila, Mattia Boeri, Giovanni Centonze, Simona Ferro, Monica Ganzinelli, Patrizia Gasparini, Veronica Huber, Massimo Milione, Luca Porcu, Claudia Proto, Giancarlo Pruneri, Diego Signorelli, Sabina Sangaletti, Lucia Sfondrini, Chiara Storti, Elena Tassi, Alberto Bardelli, Silvia Marsoni, Valter Torri, Claudio Tripodo, Mario Paolo Colombo, Andrea Anichini, Licia Rivoltini, Andrea Balsari, Gabriella Sozzi, Marina Chiara Garassino
Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
published pages: , ISSN: 1078-0432, DOI: 10.1158/1078-0432.ccr-18-1390
|Clinical Cancer Research||2020-02-25|
Veronica Huber, Viviana Vallacchi, Viktor Fleming, Xiaoying Hu, Agata Cova, Matteo Dugo, Eriomina Shahaj, Roberta Sulsenti, Elisabetta Vergani, Paola Filipazzi, Angela De Laurentiis, Luca Lalli, Lorenza Di Guardo, Roberto Patuzzo, Barbara Vergani, Elena Casiraghi, Mara Cossa, Ambra Gualeni, Valentina Bollati, Flavio Arienti, Filippo De Braud, Luigi Mariani, Antonello Villa, Peter Altevogt, Viktor Umansky, Monica Rodolfo, Licia Rivoltini
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
published pages: 5505-5516, ISSN: 0021-9738, DOI: 10.1172/jci98060
|Journal of Clinical Investigation 128/12||2020-02-25|
Valerie L. Herrmann, Daniel E. Wieland, Daniel F. Legler, Valentin Wittmann, Marcus Groettrup
The STEAP1 262-270 peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice-A new approach to immunotherapy against prostate carcinoma
published pages: 456-468, ISSN: 0270-4137, DOI: 10.1002/pros.23136
|The Prostate 76/5||2020-02-25|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRECIOUS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PRECIOUS" are provided by the European Opendata Portal: CORDIS opendata.
Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regenerationRead More
Integration of Nano- and Biotechnology for beta-cell and islet TransplantationRead More
NanoSTARS imaging for STEM cell therapy for arthritic jointsRead More